Questions | Consensus | |
---|---|---|
Pre-collapse (%) | Post-collapse (%) | |
Pathway of diagnosis of BC | Â | Â |
1. When patients are diagnosed with a bladder polyp, how many of them will undergo TURBT? | 95 | 90 |
2. How many patients do nothing? | 5 | 10 |
 a. If they choose to do nothing, how many patients will come back and have a late TURBT? | 65 | 60 |
 b. If they choose to do nothing, how many patients will never come back? | 35 | 40 |
Pathway of low-risk BC | Â | Â |
1. How many patients do the optimal treatment and follow-up? | 50 | 30 |
2. How many patients do the suboptimal treatment and follow-up? | 30 | 40 |
3. How many patients do not do treatment and follow-up? | 20 | 30 |
Pathway of intermediate-risk BC | Â | Â |
1. How many patients do the optimal treatment and follow-up? | 40 | 30 |
2. How many patients do the suboptimal treatment and follow-up? | 50 | 50 |
3. How many patients do not do treatment and follow-up? | 10 | 20 |
Pathway of high-risk BC | Â | Â |
1. How many patients do the optimal treatment and follow-up? | 30 | 20 |
2. How many patients do the suboptimal treatment and follow-up? | 65 | 70 |
3. How many patients do not do treatment and follow-up? | 5 | 10 |
Pathway of very high-risk BC | Â | Â |
1. How many patients do the optimal treatment and follow-up? | 30 | 20 |
2. How many patients do the suboptimal treatment and follow-up? | 65 | 70 |
3. How many patients do not do treatment and follow-up? | 5 | 10 |
Pathway of invasive risk BC | Â | Â |
1. How many patients do the optimal treatment and follow-up? | 80 | 60 |
 a. In the optimal scenario, how many do neoadjuvant chemotherapy + radical cystectomy? | 80 | 90 |
 b. In the optimal scenario, how many do TMT? | 20 | 10 |
2. How many patients do the suboptimal treatment and follow-up? | 15 | 30 |
3. How many patients do not do treatment and follow-up? | 5 | 10 |
Pathway of metastatic risk BC | Â | Â |
1. How many patients do treatment and follow-up? | 90 | 80 |
 a. How many patients undertake chemotherapy in the first line? | 85 | 85 |
 b. How many patients undertake immunotherapy in the first line? | 15 | 15 |
2. How many do not do treatment and follow-up? | 10 | 20 |